Eculizumab binds specifically to C5 and blocks its cleavage to C5a and C5b. Complement proximal functions are preserved:
- opsonization of microorganisms
- clearance of immune complexes

Terminal complement activation is inhibited
→ increased susceptibility to meningococcal infections